# A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia

> **NCT01592110** · PHASE1 · COMPLETED · sponsor: **Zogenix, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** risperidone-SABER
- **OTHER:** ZX003:risperidone-SABER and the DosePro System
- **DRUG:** risperidone-SABER
- **DRUG:** Risperidone-SABER

## Key facts

- **NCT ID:** NCT01592110
- **Lead sponsor:** Zogenix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01592110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01592110, "A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01592110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*